Journal Mobile Options
Table of Contents
Vol. 129, No. 2, 2013
Issue release date: February 2013
Acta Haematol 2013;129:96–100
(DOI:10.1159/000342964)

Severe Neutropenia in Patients with Chronic Hepatitis C: A Benign Condition

Sheehan V. · Weir A. · Waters B.
aHematology Center, Department of Pediatrics, Baylor College of Medicine, Houston, Tex., and bVeterans Affairs Medical Center and University of Tennessee Health Sciences Center, Memphis, Tenn., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background/Aims: Patients with chronic hepatitis C virus (HCV) infection may develop neutropenia, which can delay or prevent treatment. Severe neutropenia, absolute neutrophil counts (ANC) ≤0.500 × 109/l, is a rare finding, with only two isolated reports published in the literature. The aim of this study was to evaluate the incidence and natural history of severe neutropenia in hepatitis C patients. Methods: The records of 685 patients with active HCV were reviewed to identify those with severe neutropenia. The laboratory parameters and clinical history data of patients with severe neutropenia were then compared to a cohort of patients with HCV patients who had the more common minor neutropenia (ANC = 1.000–1.500 109/l). Results: There was no significant difference in race, MELD (Model for End Stage Liver Disease) scores, portal hypertension, splenomegaly, viral load, viral type, or hemoglobin or platelet levels. Neither group suffered serious systemic infections. Conclusions: Severe neutropenia in HCV patients is underreported and not associated with serious HCV complications such as elevated MELD score or cirrhosis. Serious infection is rare and patients respond well to granulocyte colony-stimulating factor. Severely neutropenic patients with HCV appear to have a benign course and may be candidates for antiviral therapy.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Alter MJ: Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13:2436–2441.
  2. Ramos-Casals M, Garcia-Carrasco M, Lopez-Medrano F, Trejo O, Forns X, Lopez-Guillermo A, Munoz C, Ingelmo M, Font J: Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. Medicine (Baltimore) 2003;82:87–96.
  3. d’Alteroche L, Assor P, Lefrou L, Senecal D, Gaudy C, Bacq Y: Severe autoimmune neutropenia and thrombopenia associated with chronic C hepatitis: effect of antiviral therapy (in French). Gastroenterol Clin Biol 2005;29:297–299.

    External Resources

  4. Dhingra K, Michels SD, Winton EF, Gordon DS: Transient bone marrow aplasia associated with non-A, non-B hepatitis. Am J Hematol 1988;29:168–171.
  5. Manzin A, Candela M, Paolucci S, Caniglia ML, Gabrielli A, Clementi M: Presence of hepatitis C virus (HCV) genomic RNA and viral replicative intermediates in bone marrow and peripheral blood mononuclear cells from HCV-infected patients. Clin Diagn Lab Immunol 1994;1:160–163.
  6. Streiff MB, Mehta S, Thomas DL: Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology 2002;35:947–952.

    External Resources

  7. Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F, Weksler B, Esteban R: Thrombocytopenia associated with chronic liver disease. J Hepatol 2008;48:1000–1007.
  8. Ufearo H, Kambal K, Onojobi GO, Nourale M, Agbemabiese C, Diaz S, Aggarwal A, Aliyu Z, Taylor RE, Gordeuk VR: Complete blood count, measures of iron status and inflammatory markers in inner-city African Americans with undiagnosed hepatitis C seropositivity. Clin Chim Acta 2010;411:653–656.
  9. Soza A, Lau DT, Khokhar MF, Conjeevaram H, Park Y, Hoofnagle JH: Resolution of chronic hepatitis B-associated autoimmune neutropenia with interferon-alpha therapy. J Pediatr Gastroenterol Nutr 2003;36:141–143.

    External Resources

  10. Narciso-Schiavon JL, Freire FC, Suarez MM, Ferrari MV, Scanhola GQ, Schiavon Lde L, de Carvalho Filho RJ, Silva AE: Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon? Eur J Gastroenterol Hepatol 2009;21:440–446.

    External Resources

  11. Williams MJ, Lawson A, Neal KR, Ryder SD, Irving WL: Autoantibodies in chronic hepatitis C virus infection and their association with disease profile. J Viral Hepat 2009;16:325–331.
  12. Klco JM, Sen S, Hansen JL, Lyngso C, Nikiforovich GV, Sheikh SP, Baranski TJ: Complement factor 5a receptor chimeras reveal the importance of lipid-facing residues in transport competence. FEBS J 2009;276:2786–2800.
  13. Radkowski M, Kubicka J, Kisiel E, Cianciana J, Navicki M, Rakela J, Laskus T: Detection of active hepatitis C virus and hepatitis G virus/GB virus C replication in bone marrow in human subjects. Blood 2000;95:3986–3989.
  14. Gabrielli A, Manzin A, Candela M, Paolucci S, Danieli MG, Clementi M: Active hepatitis C virus infection in bone marrow and peripheral blood mononuclear cells from patients with mixed cryoglobulinaemia. Clin Exp Immunol 1994;97:87–93.
  15. Sansonno D, Lotesoriere C, Cornacchiulo V, Fanelli M, Gatti P, Iodice G, Racenelli V, Dammacco F: Hepatitis C virus infection involves CD34(+) hematopoietic progenitor cells in hepatitis C virus chronic carriers. Blood 1998;92:3328–3337.
  16. Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP: Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med 2007;146:486–492.

    External Resources

  17. Ho SB, Aqel B, Dieperink E, Liu S, Tetrick L, Falck-Ytter Y, DeComarmond C, Smith CL, McKee DD, Boyd W, Kulig CC, Bini EJ: U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for ‘difficult-to-treat’ HCV genotype 1 patients. Dig Dis Sci 2011;56:880–888.
  18. Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335–1374.
  19. Bravo AA, Sheth SG, Chopra S: Liver biopsy. N Engl J Med 2001;344:495–500.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50